Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of ...
The American Journal of Managed Care

Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...
AOL

Newly Published Phase III Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYS: TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today the publication of a pre-planned analysis of the ...
Targeted Oncology

Adjuvant I-O Combination Tied to Early QoL Declines in RCC

Adjuvant therapy with durvalumab (Imfinzi) and tremelimumab-actl (Imjudo) in patients with resected RCC was associated with early reductions in patient-reported quality of life (QoL), according to ...